PIOS ratio: predicting the best response of non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors

Autor: Anastasia E. Kottorou, Achilleas Nikolakopoulos, Haralabos P. Kalofonos, Angelos Koutras, Thomas Makatsoris, Elias Liolis, Foteinos-Ioannis Dimitrakopoulos, Ioannis Pyrousis, Theodora Frantzi, Foteini Kalofonou
Rok vydání: 2020
Předmět:
Zdroj: Journal of Clinical Oncology. 38:e21507-e21507
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2020.38.15_suppl.e21507
Popis: e21507 Background: With the exception of programmed death ligand 1 (PD-L1) expression and Tumour Mutational Burden (TMB), which have entered clinical practice, no other clinically useful predictive biomarker for immune checkpoint inhibitors (ICIs) has been established in the daily practice. The purpose of this study was to develop a novel, non-interventional and clinically useful predictive score for NSCLC patients with advanced disease treated with ICIs. Methods: Eighty-nine patients with advanced and histologically confirmed NSCLC (stages III and IV), treated with immunotherapy (nivolumab, pembrolizumab, atezolizumab), were enrolled in the current study. Clinicopathological data as well response rates and clinical outcome data were collected. Based on this data and using a regression model, we developed a predictive score (Patras Immunotherapy Score-PIOS) with regard to the best response to ICIs. Best overall responses (BOR) were based on the immune-based therapeutics (iRECIST) criteria. Results: Four of the studied parameters -Performance Status (PS), Body Mass Index (BMI), age and lines of treatment (LOT)- were incorporated in our formula (PS *BMI/ LOT*age) giving rise to PIOS. This score was strongly associated with BOR, with patients of a good response (SD, PR or CR) having higher PIOS compared to patients with progression disease (PD) (p
Databáze: OpenAIRE
Externí odkaz: